Flanagan, John J

Catalytic in vivo protein knockdown by small-molecule PROTACs

Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 1,356

The pharmacological chaperone 1‐deoxygalactonojirimycin increases α‐galactosidase A levels in Fabry patient cell lines

Benjamin, E. R., Flanagan, J. J., Schilling, A., Chang, H. H., Agarwal, L., Katz, E., Wu, X., Pine, C., Wustman, B., Desnick, R. J., et al. (2009) · Journal of Inherited Metabolic Disease

Lysosomal Storage Disorders ResearchGlycogen Storage Diseases and Myoclonus

Cited by 173

Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer

Snyder, L. B., Flanagan, J. J., Qian, Y., Gough, S. M., Andreoli, M., Bookbinder, M., Cadelina, G., Bradley, J., Rousseau, E., Chandler, J., et al. (2021) · Cancer Research

Protein Degradation and InhibitorsEstrogen and related hormone effects

Cited by 126

Does the Bacteremia Observed in Hemorrhagic Shock Have Clinical Significance?: A Study in Germ-Free Animals

RUSH, B. F., REDAN, J. A., FLANAGAN, J. J., HENEGHAN, J. B., HSIEH, J., MURPHY, T. F., SMITH, S., & MACHIEDO, G. W. (1989) · Annals of Surgery

Sepsis Diagnosis and TreatmentTrauma, Hemostasis, Coagulopathy, Resuscitation

Cited by 73